Anixa Biosciences (NASDAQ:ANIX) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $10.00 target price on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Anixa Biosciences Price Performance

ANIX opened at $2.13 on Tuesday. Anixa Biosciences has a fifty-two week low of $2.07 and a fifty-two week high of $5.13. The firm has a market capitalization of $68.54 million, a PE ratio of -5.46 and a beta of 0.90. The company’s 50-day moving average is $2.89 and its 200 day moving average is $3.03.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Friday, January 10th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. As a group, analysts expect that Anixa Biosciences will post -0.42 EPS for the current year.

Hedge Funds Weigh In On Anixa Biosciences

Several hedge funds have recently modified their holdings of ANIX. International Assets Investment Management LLC increased its position in shares of Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after acquiring an additional 23,800 shares during the last quarter. Virtu Financial LLC bought a new position in Anixa Biosciences in the 3rd quarter valued at $34,000. Westside Investment Management Inc. grew its stake in Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares during the period. Concorde Asset Management LLC purchased a new stake in shares of Anixa Biosciences during the 2nd quarter valued at $31,000. Finally, Tyler Stone Wealth Management raised its stake in shares of Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after purchasing an additional 21,008 shares during the period. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.